Reactivities of CD8 T cells to mutated neo-antigens in lung malignancies

CD8 T 细胞对肺恶性肿瘤中突变新抗原的反应性

• 批准号: nhmrc : GNT1107091
• 负责人: A/Pr Mark Watson
• 金额: $ 66.2万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/reactivities-cd8-t-lung-malignancies/1346554
• 关键词: Reactivities; CD8; cells; mutated; neo

Tumours express mutated proteins (called ‘neo-antigens’) which can be targets of powerful killer T cells which can destroy cancer cells. To understand why these cells fail to cure most cancers we will study neo-antigens identified by modern DNA sequencing methods to identify these neo-antigens & the responses to them. Then it will be possible to design trials in individual patients, e.g. personalised vaccines to ‘force’ the immune system to attack cells bearing these neo-antigens.

肿瘤表达突变的蛋白质（称为“新抗原”），它可以成为强大的杀伤T细胞的目标，T细胞可以摧毁癌细胞。为了理解为什么这些细胞不能治愈大多数癌症，我们将研究由现代DNA测序方法鉴定的新抗原，以鉴定这些新抗原和对它们的反应。然后就有可能设计针对个体患者的试验，例如，个性化疫苗来“迫使”免疫系统攻击携带这些新抗原的细胞。